BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36394838)

  • 1. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
    Liau LM; Ashkan K; Brem S; Campian JL; Trusheim JE; Iwamoto FM; Tran DD; Ansstas G; Cobbs CS; Heth JA; Salacz ME; D'Andre S; Aiken RD; Moshel YA; Nam JY; Pillainayagam CP; Wagner SA; Walter KA; Chaudhary R; Goldlust SA; Lee IY; Bota DA; Elinzano H; Grewal J; Lillehei K; Mikkelsen T; Walbert T; Abram S; Brenner AJ; Ewend MG; Khagi S; Lovick DS; Portnow J; Kim L; Loudon WG; Martinez NL; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Giglio P; Gligich O; Krex D; Lindhorst SM; Lutzky J; Meisel HJ; Nadji-Ohl M; Sanchin L; Sloan A; Taylor LP; Wu JK; Dunbar EM; Etame AB; Kesari S; Mathieu D; Piccioni DE; Baskin DS; Lacroix M; May SA; New PZ; Pluard TJ; Toms SA; Tse V; Peak S; Villano JL; Battiste JD; Mulholland PJ; Pearlman ML; Petrecca K; Schulder M; Prins RM; Boynton AL; Bosch ML
    JAMA Oncol; 2023 Jan; 9(1):112-121. PubMed ID: 36394838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
    Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
    J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
    Olivier T; Migliorini D
    Rev Neurol (Paris); 2023 Jun; 179(5):502-505. PubMed ID: 37012085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
    JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
    Cloughesy TF; Petrecca K; Walbert T; Butowski N; Salacz M; Perry J; Damek D; Bota D; Bettegowda C; Zhu JJ; Iwamoto F; Placantonakis D; Kim L; Elder B; Kaptain G; Cachia D; Moshel Y; Brem S; Piccioni D; Landolfi J; Chen CC; Gruber H; Rao AR; Hogan D; Accomando W; Ostertag D; Montellano TT; Kheoh T; Kabbinavar F; Vogelbaum MA
    JAMA Oncol; 2020 Dec; 6(12):1939-1946. PubMed ID: 33119048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.
    Werlenius K; Kinhult S; Solheim TS; Magelssen H; Löfgren D; Mudaisi M; Hylin S; Bartek J; Strandéus M; Lindskog M; Rashid HB; Carstam L; Gulati S; Solheim O; Bartek J; Salvesen Ø; Jakola AS
    JAMA Netw Open; 2023 Mar; 6(3):e234149. PubMed ID: 37000452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
    de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
    J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
    Ahluwalia MS; Reardon DA; Abad AP; Curry WT; Wong ET; Figel SA; Mechtler LL; Peereboom DM; Hutson AD; Withers HG; Liu S; Belal AN; Qiu J; Mogensen KM; Dharma SS; Dhawan A; Birkemeier MT; Casucci DM; Ciesielski MJ; Fenstermaker RA
    J Clin Oncol; 2023 Mar; 41(7):1453-1465. PubMed ID: 36521103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
    J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
    Hdeib A; Sloan AE
    CNS Oncol; 2015; 4(2):63-9. PubMed ID: 25768330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
    Wen PY; Reardon DA; Armstrong TS; Phuphanich S; Aiken RD; Landolfi JC; Curry WT; Zhu JJ; Glantz M; Peereboom DM; Markert JM; LaRocca R; O'Rourke DM; Fink K; Kim L; Gruber M; Lesser GJ; Pan E; Kesari S; Muzikansky A; Pinilla C; Santos RG; Yu JS
    Clin Cancer Res; 2019 Oct; 25(19):5799-5807. PubMed ID: 31320597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
    Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
    Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
    JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
    JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open.
    Gatto L; Di Nunno V; Tosoni A; Bartolini S; Ranieri L; Franceschi E
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
    Guo C; Yang Q; Xu P; Deng M; Jiang T; Cai L; Li J; Sai K; Xi S; Ouyang H; Liu M; Li X; Li Z; Ni X; Cao X; Li C; Wu S; Du X; Su J; Xue X; Wang Y; Li G; Qin Z; Yang H; Zhou T; Liu J; Hu X; Wang J; Jiang X; Lin F; Zhang X; Ke C; Lv X; Lv Y; Hu W; Zeng J; Chen Z; Zhong S; Wang H; Chen Y; Zhang J; Li D; Mou Y; Chen Z
    JAMA Netw Open; 2023 Jan; 6(1):e2253285. PubMed ID: 36705923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
    Lim M; Weller M; Idbaih A; Steinbach J; Finocchiaro G; Raval RR; Ansstas G; Baehring J; Taylor JW; Honnorat J; Petrecca K; De Vos F; Wick A; Sumrall A; Sahebjam S; Mellinghoff IK; Kinoshita M; Roberts M; Slepetis R; Warad D; Leung D; Lee M; Reardon DA; Omuro A
    Neuro Oncol; 2022 Nov; 24(11):1935-1949. PubMed ID: 35511454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
    Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
    Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.